The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy
Abstract
The Food and Drug Administration documents the receipt of 12 case reports of severe myopathy or rhabdomyolysis associated with concomitant use of lovastatin and gemfibrozil, including 10 voluntary postmarketing, and 2 required, reports. All patients had serum creatine kinase levels of more than 10,000 U/L, 4 tested showed myoglobinuria, and 5 had acute renal failure. The patients' symptoms resolved when both drugs were discontinued. For the first year of marketing of lovastatin, spontaneous reports of myopathy with documentation of creatine kinase level were reviewed for the use of lovastatin, gemfibrozil, and combination therapy. The median creatine kinase level in reports involving concomitant lovastatin and gemfibrozil use was 15,250 U/L, 20 times that in reports with gemfibrozil use alone and 30 times that in reports with lovastatin use alone. Because of the potential for severe myopathy and life-threatening rhabdomyolysis, and given alternative drug combinations for treating hyperlipoproteinemia, the use of lovastatin in combination with gemfibrozil is to be discouraged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957
Hulley, S. B., Rosenman, R. H., Bawol, R. D., & Brand, R. J. (1980) · New England Journal of Medicine · doi:10.1056/nejm198006193022503 · Cited by 702
PLASMA TRIGLYCERIDE AS A RISK FACTOR FOR CORONARY HEART DISEASE
AUSTIN, M. A. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115130 · Cited by 352
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335
Rhabdomyolysis in Patients Receiving Lovastatin after Cardiac Transplantation
(1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180111 · Cited by 292
Myolysis and Acute Renal Failure in a Heart-Transplant Recipient Receiving Lovastatin
(1988) · New England Journal of Medicine · doi:10.1056/nejm198801073180110 · Cited by 255
Corpier, C. L. (1988) · JAMA · doi:10.1001/jama.260.2.239 · Cited by 237
Kane, J. P., Malloy, M. J., Tun, P., Phillips, N. R., Freedman, D. D., Williams, M. L., Rowe, J. S., & Havel, R. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198101293040502 · Cited by 193
Cited by
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
Writing Committee Members:, Pasternak, R. C., Smith, S. C., Bairey-Merz, C. N., Grundy, S. M., Cleeman, J. I., & Lenfant, C. (2002) · Circulation · doi:10.1161/01.cir.0000032466.44170.44 · Cited by 1,088
Drug Treatment of Lipid Disorders
Knopp, R. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410707 · Cited by 845
Metadata
- Authors
- Pierce, L. R.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1990-07-04
- Volume
- 264
- Issue
- 1
- Pages
- 71
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2159042889
- Cited by
- 428
- References
- 30
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy. https://app.cochat.ai/papers/10.1001/jama.1990.03450010075034
- The paper
- Pierce, L. R. (1990). Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1990.03450010075034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.